ZIC2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

ZIC2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

ZIC2 (HPE5) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and pancreas. It is a key regulator of cell proliferation and has been linked to several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified ZIC2 as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZIC2 has been shown to play a role in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer.

ZIC2 has also been linked to a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and can lead to a range of symptoms, including cognitive decline, tremors, and difficulty with daily activities.

In addition to its potential role in neurodegenerative diseases, ZIC2 has also been shown to play a key role in the development and progression of autoimmune disorders. These conditions occur when the immune system attacks the body's own tissues, leading to a range of symptoms, including inflammation, pain, and fatigue.

ZIC2 has been shown to contribute to the development and progression of autoimmune disorders, including multiple sclerosis and rheumatoid arthritis. It is also possible that ZIC2 could be used as a potential drug target for these conditions.

The potential uses of ZIC2 as a drug target are significant, given its role in the regulation of cell proliferation and its involvement in a number of diseases. ZIC2 has the potential to be used as a treatment for a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

In the future, researchers will continue to study the role of ZIC2 in the development and progression of disease. They may also conduct experiments to see if ZIC2 can be used as a potential drug target for a variety of conditions. If these studies are successful, ZIC2 could have a significant impact on the treatment of a wide range of diseases.

Protein Name: Zic Family Member 2

Functions: Acts as a transcriptional activator or repressor. Plays important roles in the early stage of organogenesis of the CNS. Activates the transcription of the serotonin transporter SERT in uncrossed ipsilateral retinal ganglion cells (iRGCs) to refine eye-specific projections in primary visual targets. Its transcriptional activity is repressed by MDFIC. Involved in the formation of the ipsilateral retinal projection at the optic chiasm midline. Drives the expression of EPHB1 on ipsilaterally projecting growth cones. Binds to the minimal GLI-consensus sequence 5'-TGGGTGGTC-3'. Associates to the basal SERT promoter region from ventrotemporal retinal segments of retinal embryos

More Common Targets

ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2 | ZNF20 | ZNF200 | ZNF202 | ZNF204P | ZNF205 | ZNF205-AS1 | ZNF207 | ZNF208 | ZNF209P | ZNF211 | ZNF212 | ZNF213 | ZNF213-AS1 | ZNF214 | ZNF215